Dr. Yang on the Efficacy of Immunotherapy in Follicular Lymphoma

Zhi Zhang Yang, MD
Published: Wednesday, Jul 05, 2017



Zhi Zhang Yang, MD, assistant professor of Medicine, Mayo Clinic, discusses the expression of LAG-3 defining exhaustion of intratumoral PD-1 antibodies and T cells and correlates poor outcomes in patients with follicular lymphoma.

PD-1 therapy is very effective in Hodgkin lymphoma; however, it is not as effective in the solid tumor or other lymphoma subtypes, explains Yang.

Scientists are attempting to add more to immunotherapy to increase the efficacy for patients with follicular lymphoma, states Yang.
 
SELECTED
LANGUAGE


Zhi Zhang Yang, MD, assistant professor of Medicine, Mayo Clinic, discusses the expression of LAG-3 defining exhaustion of intratumoral PD-1 antibodies and T cells and correlates poor outcomes in patients with follicular lymphoma.

PD-1 therapy is very effective in Hodgkin lymphoma; however, it is not as effective in the solid tumor or other lymphoma subtypes, explains Yang.

Scientists are attempting to add more to immunotherapy to increase the efficacy for patients with follicular lymphoma, states Yang.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication
x